Residency · Residency · Dermatology

Morphea and Systemic Sclerosis: Distinguishing Localized from Systemic Disease

Overview

Morphea (localized scleroderma) and systemic sclerosis (SSc) are fibrosing disorders characterized by excessive collagen deposition. Despite sharing histologic features, they are fundamentally different diseases. Morphea involves skin and subcutaneous tissue without internal organ fibrosis and does not progress to systemic sclerosis. Systemic sclerosis, by contrast, is a multi-organ fibrosing disease with skin, vascular, pulmonary, gastrointestinal, renal, and cardiac involvement. The key clinical distinction is that Raynaud phenomenon and nailfold capillary changes are present in SSc but absent in morphea.

Morphea (Localized Scleroderma)

Pathogenesis

The pathogenesis of morphea involves activation of fibroblasts with excessive collagen deposition, vascular damage and endothelial dysfunction as an early event, and a Th2-polarized immune response in which IL-4, IL-13, and TGF-beta drive fibrosis. An association with trauma, radiation therapy, and Borrelia burgdorferi has been reported, though the Borrelia connection remains controversial and is supported primarily by European data.

Classification (Subtypes)

Plaque Morphea (Most Common)

Plaque morphea presents as well-circumscribed, indurated, oval plaques. During the active phase, these plaques display a violaceous (lilac-colored) border with a central waxy, ivory-white sclerotic center. The lilac ring at the expanding edge is the key clinical indicator of disease activity. In the inactive phase, the plaque becomes hyperpigmented or hypopigmented and atrophic, without a lilac ring. Plaque morphea is most common on the trunk and is usually self-limited, lasting 3-5 years.

Linear Morphea

Linear morphea follows a band-like distribution along Blaschko lines or along an extremity and is the most common subtype in children. It can cause significant morbidity including joint contractures, limb length discrepancy, and growth restriction. En coup de sabre is linear morphea of the forehead and scalp that produces a depression of underlying tissue, potentially involving deeper structures such as muscle and bone, and overlapping with Parry-Romberg syndrome (progressive hemifacial atrophy). Linear morphea requires early aggressive treatment to prevent permanent sequelae.

Generalized Morphea

Generalized morphea is defined as four or more plaques involving two or more body regions, resulting in more extensive fibrosis and greater functional impairment. It must be distinguished from systemic sclerosis by confirming the absence of Raynaud phenomenon, sclerodactyly, nailfold changes, and internal organ involvement.

Deep Morphea (Morphea Profunda)

Deep morphea involves the deep dermis, subcutaneous fat, fascia, and/or muscle. It presents as firm, bound-down plaques without significant surface change and may produce a "groove" sign (a linear depression overlying involved fascia). Eosinophilic fasciitis (Shulman syndrome) falls within this spectrum.

Pansclerotic Morphea

Pansclerotic morphea is a severe, rare variant with circumferential involvement of the trunk and/or extremities. It can lead to severe disability, joint contractures, and rarely squamous cell carcinoma arising in chronic lesions. Disabling pansclerotic morphea of children is a progressive, debilitating form.

<image>Clinical photographs showing morphea subtypes: plaque morphea with characteristic lilac ring and ivory center, linear morphea of the extremity causing limb length discrepancy, and en coup de sabre on the forehead</image>

Histopathology of Morphea

In the early inflammatory phase, there is a perivascular lymphocytic and plasma cell infiltrate in the deep dermis and subcutis, mild collagen thickening, and eccrine coils that appear "trapped" in the mid-dermis as collagen expands around them. In the established sclerotic phase, dense, homogenized, eosinophilic collagen replaces the entire reticular dermis, adnexal structures (sweat glands, hair follicles) and periadnexal fat are lost, thickened collagen bundles extend into subcutaneous fat, the inflammatory infiltrate diminishes or disappears, and eccrine glands become entrapped high in the dermis. Morphea is distinguished from normal skin by the loss of spaces between collagen bundles, thickened collagen extending to the subcutis, and adnexal entrapment.

Evaluation of Morphea

Clinical assessment includes evaluation of skin thickness (modified Rodnan skin score for SSc; localized skin score for morphea), measurement of lesion size, and functional assessment of range of motion. MRI is indicated for deep morphea and en coup de sabre to assess the depth of involvement including fascial, muscle, and bone involvement. Peripheral eosinophilia may be present, especially in eosinophilic fasciitis. ANA is positive in approximately 25-50% of morphea patients but is not diagnostic. Anti-histone antibodies are present in some cases of generalized morphea. Anti-Scl-70 and anti-centromere antibodies should be negative in morphea; if positive, the diagnosis should be reconsidered. Ruling out SSc requires checking for Raynaud phenomenon, sclerodactyly, nailfold capillaroscopy findings, ANA pattern, and SSc-specific antibodies.

Treatment of Morphea

Limited plaque morphea is managed with topical high-potency corticosteroids, topical calcipotriene, and topical tacrolimus, along with phototherapy (UVA1). For active or progressive morphea, UVA1 phototherapy at medium dose (50 J/cm2) has the most evidence and works by softening sclerotic plaques and reducing inflammation. For linear morphea in children, en coup de sabre, and generalized morphea, methotrexate (15-25 mg/week) combined with a short course of systemic corticosteroids (initial 2-3 month pulse) is first-line per consensus guidelines. Mycophenolate mofetil serves as an alternative to methotrexate for refractory cases. Physical and occupational therapy are essential for joint contractures in linear morphea. Surgical reconstruction with fat grafting or tissue filler can address cosmetic deformity in en coup de sabre after the disease becomes quiescent.

Systemic Sclerosis (Scleroderma)

Classification

Limited cutaneous SSc (lcSSc) involves skin fibrosis distal to the elbows and knees plus the face. It was formerly known as "CREST syndrome" (Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasia). Anti-centromere antibodies are present in approximately 60-80% of cases. Progression is slower, but there is risk of pulmonary arterial hypertension (PAH). Diffuse cutaneous SSc (dcSSc) involves skin fibrosis proximal to the elbows and knees and the trunk. Anti-Scl-70 (anti-topoisomerase I) antibodies are found in approximately 30-40% of cases. This form is more aggressive with higher risk of interstitial lung disease and scleroderma renal crisis. Skin involvement progresses rapidly in the first 3-5 years, then may stabilize.

Skin Findings in SSc

Raynaud Phenomenon

Raynaud phenomenon is often the first manifestation and may precede other findings by years. It causes triphasic color change: white (vasospasm), blue (cyanosis), then red (reperfusion), and is present in over 95% of SSc patients. Nailfold capillaroscopy reveals dilated, tortuous, "giant" capillary loops, avascular areas, and microhemorrhages, which help distinguish primary Raynaud (normal capillaries) from secondary Raynaud with SSc-pattern changes.

Sclerodactyly

Sclerodactyly involves skin tightening of the fingers with waxy, bound-down skin. In the early edematous (puffy) phase of SSc, "sausage fingers" may be seen. Progressive loss of hand function and flexion contractures follow, along with digital pitting scars from ischemic events and digital ulcers from vascular insufficiency.

Facial Involvement

Facial involvement includes microstomia (reduced oral aperture), radial perioral furrowing, a beaked nose from thinning of the nasal tip, matted telangiectasias on the face and hands, and reduced facial expression resulting in mask-like facies.

Other Skin Findings

Telangiectasias appear as matted, punctate telangiectasias on the face, lips, palms, and hands. Calcinosis cutis produces subcutaneous calcium deposits on the fingers, extensor surfaces, and ischial tuberosities that can ulcerate and cause pain and infection. Salt-and-pepper dyspigmentation shows perifollicular hypopigmentation with surrounding hyperpigmentation on the trunk. Pruritus can be severe, especially in early diffuse disease.

<image>Clinical features of systemic sclerosis: sclerodactyly with digital pitting scars, nailfold capillaroscopy showing dilated tortuous capillary loops, matted telangiectasias on the face, and calcinosis cutis of the fingers</image>

Autoantibodies in SSc

Anti-centromere (ACA) antibodies associate with limited cutaneous SSc, PAH, and low ILD risk. Anti-Scl-70 (anti-topoisomerase I) antibodies associate with diffuse cutaneous SSc, ILD, and poor prognosis. Anti-RNA polymerase III antibodies associate with diffuse cutaneous SSc, carry the highest risk of scleroderma renal crisis, and are associated with malignancy. Anti-U1 RNP antibodies suggest mixed connective tissue disease overlap with pulmonary hypertension. Anti-PM-Scl antibodies indicate SSc-myositis overlap. Anti-Th/To antibodies occur in limited SSc with ILD risk.

Internal Organ Involvement

Pulmonary involvement includes ILD (the most common cause of death) and PAH, screened for with PFTs and echocardiogram annually. Gastrointestinal involvement includes esophageal dysmotility (over 90%), GERD, gastric antral vascular ectasia (GAVE or "watermelon stomach"), and intestinal dysmotility. Renal involvement manifests as scleroderma renal crisis, an acute hypertensive crisis with microangiopathic hemolytic anemia treated with ACE inhibitors; corticosteroids should be avoided as they may precipitate renal crisis. Cardiac involvement includes pericarditis, myocardial fibrosis, and arrhythmias. Musculoskeletal involvement includes arthralgia, tendon friction rubs (a poor prognostic sign), and myopathy.

Treatment of SSc

No disease-modifying therapy cures SSc; treatment is organ-specific. Raynaud phenomenon is managed with calcium channel blockers (nifedipine, amlodipine), PDE5 inhibitors (sildenafil), and IV prostacyclins (iloprost) for digital ulcers. Skin fibrosis is treated with methotrexate for early diffuse disease, mycophenolate mofetil, tocilizumab (anti-IL-6), and nintedanib (emerging evidence). ILD is managed with mycophenolate mofetil (SLS II trial), nintedanib (SENSCIS trial), cyclophosphamide, and autologous stem cell transplant for severe progressive disease. PAH is treated with endothelin receptor antagonists (bosentan), PDE5 inhibitors, prostacyclin analogs, and riociguat. Renal crisis is treated with ACE inhibitors (captopril). GI involvement is managed with PPIs for GERD and prokinetics for dysmotility.

Distinguishing Morphea from SSc

Clinical Pearls

Morphea does not progress to systemic sclerosis. These are fundamentally different diseases despite sharing histologic features of dermal sclerosis. The lilac ring at the periphery of a morphea plaque indicates active inflammation and is the key clinical marker of disease activity; its absence suggests the plaque is "burned out." Linear morphea in children requires early and aggressive systemic treatment with methotrexate to prevent growth disturbances, limb length discrepancy, and joint contractures. In systemic sclerosis, nailfold capillaroscopy showing giant capillary loops and avascular areas is a simple, non-invasive way to distinguish secondary Raynaud (SSc) from primary Raynaud. Anti-RNA polymerase III antibodies in SSc are associated with both scleroderma renal crisis and an increased risk of synchronous malignancy within 3 years of diagnosis.

References

• Fett N, Werth VP. Update on morphea: Part I and II. J Am Acad Dermatol. 2011;64(2):217-228, 231-242
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699
• Li SC, et al. Consensus treatment plans for moderate to severe pediatric localized scleroderma. Arthritis Care Res. 2012;64(8):1175-1185
• Tashkin DP, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II). Lancet Respir Med. 2016;4(9):708-719
• Kreuter A, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016;14(2):199-216

Read this lecture as Markdown